Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Icatibant (Firazyr)
Also known as: Firazyr, HOE 140, JE049
Ninety-seven percent of patients get injection site reactions. That number looks alarming until you realize it means the drug is doing its job. Icatibant (Firazyr) is an FDA-approved bradykinin B2 receptor antagonist, a synthetic decapeptide that blocks the exact molecule driving hereditary angioedema swelling. The FAST-3 trial (n=56) confirmed clinically meaningful relief within about 2 hours. It won't prevent attacks. That's not its role. Icatibant is on-demand rescue therapy for adults with HAE types I and II, delivered through a pre-filled syringe that requires zero mixing, zero reconstitution, and zero IV access.
What Is Icatibant (Firazyr)?
Thirty milligrams in a pre-filled syringe. That's the entire dosing protocol for icatibant, also sold as Firazyr (CAS 130308-48-4). The drug is a synthetic decapeptide (H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH) containing five non-natural amino acids engineered to resist enzymatic breakdown. Where natural bradykinin survives roughly 15 to 30 seconds in plasma, icatibant holds on for 1 to 2 hours.
The mechanism is straightforward competitive antagonism. Bradykinin binds the B2 receptor on vascular endothelial cells, triggering vasodilation and plasma leakage. Icatibant sits in that same binding pocket with high affinity (Ki approximately 0.7 nM) and does nothing, blocking the downstream cascade that produces swelling. Think of it as a lock filled with a blank key.
Hereditary angioedema affects roughly 1 in 50,000 people. Attacks hit the extremities, gut, and face; the most dangerous involve the larynx. Before targeted therapies, laryngeal attacks carried real mortality risk. Icatibant earned EMA approval in 2008 and FDA approval in 2011 based on the FAST-3 trial (NCT00912093, n=56 in the icatibant arm). Median time to clinically significant relief landed at approximately 2 hours for cutaneous and abdominal attacks, statistically superior to placebo [1].
The drug is manufactured by Takeda under full GMP standards. No compounded versions exist in the US market. Retail pricing runs $11,147 to $12,302 per syringe, making insurance coverage or patient assistance programs practically mandatory.
How Icatibant (Firazyr) Works
Icatibant is a selective, competitive antagonist at the bradykinin B2 receptor (BDKRB2). This is a G-protein coupled receptor expressed on vascular endothelial cells, smooth muscle, and sensory neurons. The peptide binds with high affinity (Ki approximately 0.7 nM), occupying the orthosteric site without activating downstream signaling.
By sitting in that binding pocket, icatibant prevents bradykinin from triggering Gq protein activation. The blocked cascade includes phospholipase C (PLC) activation, inositol trisphosphate (IP3)-mediated calcium release, and endothelial nitric oxide synthase (eNOS) activation. Without that cascade firing, the vasodilation and endothelial gap formation responsible for HAE edema simply don't happen.
Selectivity matters here. Icatibant has no meaningful affinity for the inducible B1 receptor. It targets the constitutive B2 receptor specifically.
The five non-natural amino acids in the sequence (D-Arg, hydroxyproline, thienylalanine, D-Tic, and Oic) give icatibant serious resistance to ACE/kininase II, aminopeptidase P, and carboxypeptidase N. Leach and colleagues mapped out the pharmacokinetics in healthy volunteers: plasma half-life was about 1.5 hours after a 30 mg dose [2]. Absolute bioavailability after subcutaneous injection is about 97%, with peak plasma concentration reached at approximately 30 minutes.
Icatibant (Firazyr) Benefits
- Icatibant benefits center on rapid, targeted relief during acute hereditary angioedema attacks.
- Median time to clinically meaningful symptom relief sits at approximately 2 hours in the FAST-3 trial (n=56 icatibant arm)[1], with many patients reporting improvement by 30 to 90 minutes.
- Pre-filled syringe design means zero reconstitution, zero mixing, zero IV access. You pull off the cap and inject. During a laryngeal attack, those saved minutes count.
- Selective B2 receptor blockade targets the direct mediator of HAE swelling, bradykinin, rather than working through indirect pathways. The drug hits the problem at its molecular source.
- Fully synthetic production eliminates blood-borne pathogen transmission risk. Unlike plasma-derived C1-INH products (Berinert, Cinryze), icatibant carries no theoretical prion or viral contamination concern.
- No tachyphylaxis or antibody formation has been detected with repeated on-demand use across clinical trial populations and over a decade of post-marketing surveillance. The second injection works as well as the first.
- Community reports from HAE patients consistently describe the drug as eliminating ER visits for the majority of cutaneous and abdominal attacks; self-treatment at home or during travel is standard practice.
Icatibant (Firazyr): Science vs Community Consensus
FDA-approved (2011) on-demand treatment for acute HAE attacks in adults ≥18.
Read the evidence (key study, limitations)
FAST-3 demonstrated statistically significant superiority over placebo in time to onset of symptom relief. Evidence is strong and unambiguous: 30 mg SC per attack is the sole established dose.
FAST-3 trial: Lumry et al., Ann Allergy Asthma Immunol, 2011 (PMID 22123383, n=56 icatibant arm); median time to clinically significant relief ~2 hours vs placebo
All pivotal trials enrolled HAE types I and II only; no RCT data in pediatric patients (<18); efficacy in HAE type III (estrogen-dependent) is not established; limited head-to-head data vs C1-INH concentrate in laryngeal attacks
HAE patients report reliable, rapid attack relief.
Read the reports (what users report 5, common issues 4)
Community is very small (HAE affects ~1/50,000 people). No off-label or performance use: exclusively medical. Overall positive sentiment with injection-site reactions and cost as primary complaints.
- Rapid onset: most patients report noticeable improvement within 30–90 minutes
- Eliminates ER visits for the majority of cutaneous and abdominal attacks
- Self-injectable without IV access; usable at home, work, or travel
- No blood-product transmission risk (fully synthetic, not plasma-derived)
- Pre-filled syringe: no mixing, no reconstitution, ready in seconds during an attack
- Injection site reactions in ~97% of patients (burning, redness, swelling at site): most resolve within hours but are uncomfortable
- Cost: brand Firazyr ~$11,000–$12,000 per syringe retail; inaccessible without insurance or patient assistance
- Significant anxiety around self-injection during a laryngeal (throat) attack when airway is at risk
- Some patients experience recurrence within 6–12h requiring a second dose
Science and community are fully aligned: 30 mg on-demand is the established dose, onset within 1–2 hours is reproduced in both trials and patient reports, and injection-site reactions are the primary adverse event in both clinical data and community experience. No off-label use exists to create divergence.
Icatibant (Firazyr) Dosage Guide
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 30 mg | Single dose |
| Moderate | 30 mg | Single dose |
| Aggressive | 30 mg | Single dose |
Icatibant arrives in a pre-filled syringe. No reconstitution math needed here, which is unusual for this platform. The syringe contains 30 mg in 3 mL (10 mg/mL concentration) with a 25-gauge, half-inch needle already attached. You're injecting the full syringe contents every time.
Store below 25 degrees Celsius. Don't freeze it. A frozen syringe is a discarded syringe. Keep it in the original packaging away from light. When traveling, bring at least 2 to 3 syringes; one may not be enough for a severe or recurrent attack.
The non-obvious thing most beginners miss: speed of injection matters. Thirty seconds minimum for the full 3 mL. Pushing faster makes the site reaction much worse. Some patients use a timer on their phone.
For laryngeal attacks, don't wait to see if the drug works before calling emergency services. Inject AND call simultaneously. Airway compromise can progress faster than icatibant's onset of action.
One more practical note: keep your attack frequency log current. If you're reaching for icatibant more than once a month, that's a signal to discuss prophylaxis options (lanadelumab, berotralstat, C1-INH replacement) with your HAE specialist.
Cycling
Icatibant is used on-demand for acute HAE attacks and is not administered on a scheduled cycling basis. Each attack is treated individually with a single 30 mg SC injection. If symptoms persist or recur, up to 2 additional doses may be given at intervals of at least 6 hours (maximum 3 injections / 90 mg per 24 hours).
Icatibant is on-demand acute rescue therapy, not a cycling compound. There is no scheduled administration: each injection treats an individual HAE attack as it occurs. The concept of "cycling" does not apply. No receptor desensitization, antibody formation, or cumulative pharmacological tolerance has been observed with long-term intermittent use across clinical trial populations.
- No cycling signs to monitor: the drug is used only when an attack occurs
- Increasing attack frequency requiring more frequent icatibant use is not a sign to cycle off icatibant: it is a clinical signal to re-evaluate prophylaxis with an HAE specialist
- No published reports of tachyphylaxis or diminishing response with repeated on-demand use
Or use the universal Peptide Calculator for any peptide.
Icatibant (Firazyr) Protocols by Goal
Expected: Clinically significant symptom relief in the majority of patients within 30 minutes to 2 hours; complete attack resolution within 6–24 hours in most cases
Monitor: Assess symptom status at 1h and 2h post-injection. If no clinically meaningful improvement by 6 hours, a second dose is permitted. For any laryngeal (throat/airway) attack: administer icatibant AND call emergency services simultaneously: do not wait to assess drug response before calling 911.
How to Inject Icatibant (Firazyr)
- 1Step 1
At the first sign of an HAE attack, retrieve one pre-filled syringe from storage. Check the expiration date. Inspect the solution; it should be clear and colorless. Discard any syringe with particles, cloudiness, or discoloration.
- 2Step 2
Clean a site on your abdomen at least 2 inches from the navel. Avoid areas with bruising, scarring, or previous injection site reactions that haven't fully resolved.
- 3Pinch a fold of abdominal skin
Insert the 25-gauge needle at a 45 to 90 degree angle.
- 4Inject the full 3 mL slowly over approximately 30 seconds
The syringe delivers 30 mg total (10 mg/mL concentration). Do not rush this step.
- 5Withdraw the needle and apply gentle pressure
Expect injection site redness, warmth, and mild swelling; this is normal and resolves within hours.
- 6Note the time of injection
Assess symptoms at 1 hour and 2 hours post-injection.
- 7Step 7
If symptoms persist or recur after 6 hours: administer a second 30 mg syringe using a different abdominal injection site.
- 8Step 8
If symptoms persist after the second dose: a third 30 mg dose may be given no sooner than 6 hours after Dose 2. Maximum is 3 injections (90 mg) per 24 hours.
- 9Step 9
For any laryngeal (throat/airway) attack: inject icatibant immediately AND call emergency services. Do not wait to evaluate drug response before calling 911.
- 10After use, dispose of the syringe in a sharps container
Do not recap the needle.
Icatibant (Firazyr) Stacking Protocols
Works With
Standard long-term prophylaxis for HAE: plasma kallikrein inhibitor (monoclonal antibody) that prevents attacks; icatibant is used on-demand for breakthrough attacks occurring despite lanadelumab prophylaxis
Lanadelumab 300 mg SC every 2–4 weeks for prevention; icatibant 30 mg SC on-demand for breakthrough acute attacks
Oral prophylaxis for HAE: plasma kallikrein inhibitor taken daily to reduce attack frequency; icatibant used on-demand for breakthrough attacks that occur despite berotralstat prophylaxis
Berotralstat 150 mg orally once daily for prevention; icatibant 30 mg SC on-demand for acute breakthrough attacks
Alternative acute HAE treatment targeting the upstream contact/complement pathway; used when icatibant is unavailable, for patients with C1-INH deficiency as the primary pathology, or sequentially by clinical preference; not typically combined with icatibant for a single attack
Either icatibant OR C1-INH concentrate for acute attack management; Haegarda (SC C1-INH) may serve a prophylaxis role separately
Avoid
ACE inhibitors act on the bradykinin/kinin system; icatibant B2 receptor blockade may reduce the antihypertensive effect of ACE inhibitors. ACE inhibitors independently cause ACE inhibitor-induced angioedema (a distinct bradykinin-mediated condition) which may be misdiagnosed as HAE, and may respond differently to icatibant. Discuss with prescribing physician before use; FDA label flags this interaction explicitly.
Estimated Cost
Pricing updated 2026-04-09
Icatibant (Firazyr) Side Effects
Injection site reactions affect approximately 97% of patients in clinical trials. That is not a typo. Erythema, swelling, warmth, burning, itching, and local pain at the abdominal injection site are expected, not exceptional. Most reactions are mild to moderate and resolve within a few hours. The key distinction: these are local pharmacological reactions, not allergic responses. True allergy would present with generalized urticaria, respiratory distress, or cardiovascular instability beyond what the HAE attack itself produces.
Injection speed directly affects site reaction severity. The full 3 mL must be delivered slowly over approximately 30 seconds. Patients who rush the injection consistently report worse local reactions. Count to 30 while pushing the plunger.
Systemic adverse effects are less common. Clinical trials flagged pyrexia, transaminase elevations, dizziness, and rash at rates modestly above placebo. Nausea and headache occurred at placebo-comparable rates in the FAST-3 and FAST-2 studies [1].
A theoretical cardiovascular concern exists and deserves honest discussion. Bradykinin has cardioprotective vasodilatory properties. Blocking B2 receptors could, in theory, attenuate those benefits. The FDA label calls out patients with acute ischemic heart disease and unstable angina as populations requiring caution. To date, no clinically meaningful cardiovascular events attributable to this mechanism have surfaced in trial data or post-marketing surveillance. But "no signal yet" and "proven safe" are different statements; the population using icatibant is small.
Patients taking ACE inhibitors face a specific interaction concern. Both icatibant and ACE inhibitors affect the bradykinin system. B2 receptor blockade may reduce the antihypertensive effect of ACE inhibitors. More importantly, ACE inhibitors can themselves trigger bradykinin-mediated angioedema, a condition that mimics HAE but may respond differently to treatment.
Pregnancy carries a Category C designation. B2 receptor blockade could theoretically affect uterine contractions and placental blood flow. No adequate human data exists.
When to seek emergency care: if symptoms don't improve after the first dose by 6 hours, if laryngeal swelling is progressing despite treatment, or if three doses in 24 hours haven't resolved the attack. Never rely solely on icatibant during a throat attack; inject AND call emergency services simultaneously.
Common Issues & Solutions
Injection site reactions (burning, redness, swelling, itching at injection site) occur in ~97% of patients: this is EXPECTED and does NOT indicate an allergic reaction. Distinguish from true allergy by absence of systemic symptoms (no generalized hives, anaphylaxis signs, or cardiovascular instability unrelated to the HAE attack itself).
Injecting too quickly: the full 3 mL must be delivered slowly over approximately 30 seconds. Rapid delivery significantly worsens local site reaction severity. Count to 30 while injecting.
Delayed injection during a laryngeal attack: icatibant works best when given early. Call emergency services AND inject icatibant in parallel; do not wait for drug response to assess whether to call 911 for throat/airway attacks.
Storage failure: pre-filled syringes must be stored below 25°C (77°F) in original packaging and must NOT be frozen. A frozen or heat-exposed syringe should be discarded and replaced; using a compromised syringe during an attack may result in subtherapeutic drug delivery.
Not having backup syringes available: for patients at risk of multi-dose attacks or laryngeal attacks, having at least 2–3 pre-filled syringes on hand at all times is critical; a single syringe may not be sufficient for severe or recurrent attacks.
Ask AI about this page
Ask AI for a second opinion on Icatibant (Firazyr) dosing and side effects
Contraindications
- Known hypersensitivity to icatibant or any excipients in the formulation
- Pediatric patients under 18 years of age (safety and efficacy not established)
- Pregnancy: Category C; B2 receptor blockade may theoretically affect uterine contractions and placental blood flow
- Patients with acute ischemic heart disease or unstable angina: theoretical concern about blocking cardioprotective bradykinin effects
- Patients within weeks of an acute stroke: bradykinin may play a role in post-ischemic neuroprotection
Drug Interactions
- ACE inhibitors (enalapril, lisinopril, ramipril): icatibant may theoretically reduce the antihypertensive effect of ACE inhibitors
- tPA and thrombolytics: bradykinin promotes endogenous tPA release; B2 blockade may modestly reduce endogenous fibrinolytic activity
- Other HAE therapies (C1-INH concentrate, ecallantide, lanadelumab): can be used sequentially, but concurrent use not formally studied
- Antihypertensives: monitor blood pressure, as the interaction between B2 blockade and other vasodilatory pathways is not fully characterized
- ACE inhibitors act on the bradykinin/kinin system; icatibant B2 receptor blockade may reduce the antihypertensive effect of ACE inhibitors. ACE inhibitors independently cause ACE inhibitor-induced angioedema (a distinct bradykinin-mediated condition) which may be misdiagnosed as HAE: and may respond differently to icatibant. Discuss with prescribing physician before use; FDA label flags this interaction explicitly.
Product Quality
Icatibant is an FDA-approved medicine made under full GMP standards. It's sold as Takeda's Firazyr and as generics approved since 2019 (10 on Drugs@FDA, 8 still marketed), all by prescription only. Compounded icatibant is not FDA-approved. Quality risk is minimal compared to research peptides.
- Only use FDA-approved icatibant (Firazyr or an approved generic) from a licensed pharmacy. Compounded icatibant formulations are not FDA-approved and have no established safety or efficacy data
- Check the expiration date on each pre-filled syringe before use, especially during an attack when cognitive load is high
- Inspect the solution visually before injecting: must be clear and colorless; discard any syringe with visible particulate matter, cloudiness, or discoloration
- Store below 25°C (77°F) in original packaging to protect from light; never freeze; never store in a car glove box or bathroom medicine cabinet where temperature fluctuates
- Carry at least 2–3 pre-filled syringes when traveling; ask the dispensing pharmacy or HAE clinic in advance about emergency resupply
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Clinical symptom assessment | 1h, 2h, and 6h after each injection | Clinically significant improvement by 2h; complete or near-complete resolution by 6–12h. Absence of any improvement by 6h warrants emergency care. |
| Blood pressure monitoring | During and after icatibant use in patients on ACE inhibitors or other antihypertensives | Not listed |
| Attack frequency log | Ongoing between attacks (patient-maintained) | Not listed |
Determines whether attack is resolving, stable, or progressing; guides decision on whether a second or third dose is needed, or whether emergency escalation is warranted
Icatibant may reduce the antihypertensive effect of ACE inhibitors via overlapping bradykinin pathway modulation; blood pressure may rise transiently
Icatibant is on-demand rescue therapy only. Increasing attack frequency (>1 attack per month, or any laryngeal attack) is a clinical indicator to reassess prophylaxis adequacy with the treating HAE specialist; does not reflect a limitation of icatibant itself
Icatibant (Firazyr) Before and After
Rapid absorption from injection site, reaching peak plasma concentration at approximately 30 minutes. B2 receptor occupancy begins within minutes. Injection site reactions typically appear immediately.
Onset of symptomatic relief for most patients. Reduction in swelling, pain, and edema as bradykinin B2 receptor blockade prevents further vascular permeability.
Continued symptom resolution as tissue edema reabsorbs. If no improvement by 6 hours, a second 30 mg dose may be administered.
Most attacks fully resolved within 12-24 hours. Icatibant largely cleared from plasma. If symptoms recur, additional doses may be given (maximum 3 doses/90 mg per 24 hours).
On-demand use, not prophylactic. No tolerance or tachyphylaxis observed with repeated use. No cumulative adverse effects reported with long-term intermittent use.
What to Expect
0 to 30 minutes: Absorption starts fast. Peak plasma concentration hits at roughly 30 minutes after abdominal injection. B2 receptor occupancy begins within minutes. Injection site reactions (redness, burning, swelling) show up almost immediately. Most patients won't feel meaningful symptom relief yet; some describe a subjective sense of the drug working by the 15 to 20 minute mark.
30 minutes to 2 hours: This is where relief begins. The FAST-3 trial pinned median time to clinically meaningful improvement at approximately 2 hours. B2 receptor blockade halts further vascular permeability and stops edema progression. Existing swelling starts to reabsorb. HAE patients commonly report noticeable reduction by 60 to 90 minutes. Abdominal attack sufferers often report faster subjective pain relief than those with cutaneous swelling. Mild dizziness or low-grade fever can occur during this window.
2 to 6 hours: Continued resolution. Tissue edema reabsorbs as bradykinin-mediated extravasation stays blocked. Icatibant plasma levels are declining toward the end of the therapeutic window. Most patients report clear improvement by 4 hours. Cutaneous attacks may take the full 6 hours for visible swelling to fully resolve. A small subset experiences symptom recurrence at 4 to 6 hours. If no improvement by 6 hours, a second 30 mg dose is permitted.
6 to 24 hours: Most attacks resolve completely within 12 to 24 hours. Icatibant is largely cleared from plasma. Per FAST-3 trial data, fewer than 20% of attacks required more than one injection. A second or third dose can be given at 6-hour minimum intervals (maximum 3 doses, 90 mg per 24 hours). Patients who need a second dose consistently report it works as well as the first.
Detailed Timeline: Science vs Community
Rapid SC absorption from abdominal fat; B2 receptor occupancy begins within minutes of injection. Peak plasma concentration reached at approximately 45 minutes (FDA label). Injection site reactions (erythema, burning, swelling) appear immediately.
Some patients describe a subjective sense of the drug "working" within 15–20 minutes; others notice the injection site reaction as the first sign. No meaningful symptom relief typically expected this early.
FAST-3 median time to clinically significant relief approximately 2 hours. B2 receptor blockade prevents further bradykinin-mediated vascular permeability and halts edema progression. Existing edema begins reabsorbing.
Majority of HAE patients report noticeable swelling reduction by 60–90 minutes. Abdominal attack patients often report faster subjective pain relief than cutaneous swellers. Some describe relief as "like a valve closing" on the swelling.
Tissue edema reabsorbs progressively as bradykinin-mediated extravasation is blocked. Icatibant plasma concentration declining toward end of therapeutic window. Second dose permitted at 6h if attack not adequately resolving.
Most patients report significant improvement by 4h. Cutaneous attacks may take the full 6h for visible swelling to resolve; abdominal attacks often fully resolved. Small subset reports symptom recurrence at 4–6h requiring a second dose.
Most attacks fully resolved within 12–24 hours. Icatibant largely cleared from plasma. Per trial data, <20% of attacks require more than one dose. A second or third dose may be administered at ≥6-hour intervals if symptoms recur or persist.
Majority of patients report complete resolution within 12h. Patients requiring multiple doses describe the second dose as equally effective as the first with no loss of response.
Pharmacokinetics
Source: FDA Firazyr label & Schwarz et al., Clin Pharmacokinet, 2014: terminal half-life ~1-2 hours after SC injection
Pharmacokinetics: Active Dose Over Time
t½ = ~1-2 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Icatibant (Firazyr) Legal?
Icatibant is FDA-approved (NDA 022150, approved August 2011) for the treatment of acute attacks of hereditary angioedema in adults 18 years and older. The European Medicines Agency approved it in 2008. It is marketed as Firazyr by Takeda (originally developed by Jerini AG, acquired by Shire).
Generic icatibant has been FDA-approved since July 2019. Drugs@FDA lists 10 generic approvals, 8 still marketed, each the same 30 mg/3 mL strength as Firazyr. All are prescription-only, and compounded icatibant is not FDA-approved.
WADA status is not applicable; icatibant has no performance-improving profile and no history of athletic misuse.
Pediatric use (under 18) is not approved. The FDA label explicitly states safety and efficacy have not been established in patients under 18 years of age.
This content is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any prescription medication. Hereditary angioedema management should be supervised by an allergist, immunologist, or HAE specialist.
Who Should Consider Icatibant (Firazyr)
- Adults 18+ with confirmed hereditary angioedema (HAE) types I and II experiencing acute attacks
- HAE patients seeking on-demand self-injectable treatment for cutaneous, abdominal, or laryngeal attacks
- Patients who prefer a synthetic (non-plasma-derived) option for HAE attack management
- Allergists and immunologists managing HAE patients in clinical practice
- Emergency physicians treating acute angioedema episodes
- Researchers studying bradykinin pathway modulation and kinin receptor pharmacology
Related Peptides
What Changed for Icatibant (Firazyr)
Peptide Schedule Research TeamReviewed Apr 8, 20267 Citations
References
- [1]Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial (Ann Allergy Asthma Immunol 2011) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Pharmacokinetics of single and repeat doses of icatibant (Leach et al., Clin Pharmacol Drug Dev 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]FDA NDA 022150
- [4]Drugs@FDA: 10 icatibant ANDAs, first approved July 2019 (ANDA 210118)
Additional References
- Firazyr (icatibant) FDA Prescribing Information (opens in a new tab)FDA Label
- Bradykinin-mediated angioedema: an update of the genetic causes and the impact of genomics (Marcelino-Rodriguez et al., Front Genet 2019) (opens in a new tab)PubMed 31611908Review
- FAST-3 trial (NCT00912093) (opens in a new tab)Clinical Trial
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Icatibant (Firazyr)?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Few. Community mentions on Reddit: Very low: HAE-specific communities (r/HeredityAngioEdema). Open r/HeredityAngioEdema (small) (opens in a new tab).
300 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Low search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.